Skip to main content

Drug Interactions between iptacopan and tiagabine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

tiaGABine iptacopan

Applies to: tiagabine and iptacopan

MONITOR: Coadministration of iptacopan may decrease the exposure of CYP450 3A4 substrates, which may reduce their clinical efficacy. According to in vitro studies, iptacopan has potential for induction of the CYP450 3A4 isoenzyme. The interaction may be particularly important for sensitive substrates or those that demonstrate a narrow therapeutic index. However, clinical data evaluating the interaction are not available.

MANAGEMENT: Caution and clinical monitoring are advised if iptacopan is to be used in combination with substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range. The prescribing information for the concomitant medication should also be consulted to assess the benefits versus risks of coadministration with CYP450 3A4 inducers and for any dosage adjustments that may be required.

References (3)
  1. (2024) "Product Information. Fabhalta (iptacopan)." Novartis Pharmaceuticals Australia Pty Ltd
  2. (2024) "Product Information. Fabhalta (iptacopan)." Novartis Pharmaceuticals, SUPPL-1
  3. Novartis Pharmaceuticals Canada Inc Product Monograph. Fabhalta (iptacopan) https://pdf.hres.ca/dpd_pm/00078186.PDF

Drug and food interactions

Moderate

tiaGABine food

Applies to: tiagabine

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (4)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer